Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone

ConditionPost Partum Hemorrhage

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexFemale

Age18-45

SponsorCairo University

About this trial

While Carbetocin is effective in reducing PPH, the combination of oxytocin, Tranexamic acid, and Ergot derivatives may offer additional benefits in high-risk populations. We hypothesize that the combination regimen will reduce PPH incidence and severity compared to Carbetocin alone and may be more cost effective

Eligibility criteria

Qualifiers

Women undergoing C-Sections.

Women between the ages of 18 and 45 years.

Singleton pregnancy.

Gestational age is equal to or more than 36 weeks.

Disqualifiers

Hemodynamically unstable or immobile patients.

Multifetal pregnancy.

Patients who are receiving prophylactic or therapeutic anticoagulation.

Known comorbidities and contraindications to the use of Ergot derivatives or Carbetocin such as hypertension or cardiovascular disorders.

Trial design

Treatments tested in this trial

Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative
Intravenous Carbetocin alone

Treatment groups

80 Participants

are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Cairo University

Lead sponsor

Source ClinicalTrials.gov